These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1381 related items for PubMed ID: 17973572

  • 1. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A.
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [Abstract] [Full Text] [Related]

  • 3. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.
    Cancer Res; 2013 Apr 15; 73(8):2428-34. PubMed ID: 23382048
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
    Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K.
    Cancer Res; 2010 Dec 15; 70(24):10402-10. PubMed ID: 21159653
    [Abstract] [Full Text] [Related]

  • 8. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS, Kobayashi S, Costa DB.
    Clin Lung Cancer; 2009 Jul 15; 10(4):281-9. PubMed ID: 19632948
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.
    Oncotarget; 2015 Dec 29; 6(42):44274-88. PubMed ID: 26517520
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
    Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST.
    Nat Med; 2012 Mar 18; 18(4):521-8. PubMed ID: 22426421
    [Abstract] [Full Text] [Related]

  • 14. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
    Song JY, Kim CS, Lee JH, Jang SJ, Lee SW, Hwang JJ, Lim C, Lee G, Seo J, Cho SY, Choi J.
    Invest New Drugs; 2013 Dec 18; 31(6):1458-65. PubMed ID: 24068620
    [Abstract] [Full Text] [Related]

  • 15. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 Jun 18; 9(6):1647-56. PubMed ID: 20530710
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK, Kim M, Lee H, Kwon Y, Cha HJ, Jang SJ, Na Y, Lee YS.
    Cell Oncol (Dordr); 2022 Oct 18; 45(5):913-930. PubMed ID: 35931945
    [Abstract] [Full Text] [Related]

  • 18. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 18; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 19. EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer.
    Wu PS, Lin MH, Hsiao JC, Lin PY, Pan SH, Chen YJ.
    Mol Cell Proteomics; 2023 Sep 18; 22(9):100624. PubMed ID: 37495186
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.